Abstract 1677P
Background
Chemotherapy (CT) often triggers physical and emotional changes impacting patients' lives, including their sexuality. Addressing sexual health (SH) issues is crucial for comprehensive cancer care. The aim of our study was to identify SH and intimacy issues in the Tunisian context among men undergoing CT.
Methods
The study was a cross-sectional, anonymous questionnaire-based study, conducted between March and May 2024 including 80 male cancer patients undergoing CT. Urological cancer patients were excluded. SH was evaluated by the EORTC Quality of Life Questionnaire Sexual Health (QLQ SH-22), which includes assessments of sexual satisfaction, sexual pain, sexual activity, treatment and partner-related issues. A higher score represents a higher level of symptomatology.
Results
Median age was 59.5 years [32-73]. Sixty-six patients (83%) were married and 79% were sexually active before the diagnosis. Colon cancer was the most common primary cancer (44%), followed by lung (20%) and pancreas (14%). Tumors were non metastatic in 55% of cases. The importance of communication about SH between doctors and patients was highlighted by 69% of respondents especially in those under 50 years old (95%). However, 59% considered it insufficient during checkups. The most commonly reported reason, cited by over half of patients (53%), was a lack of initiative on the part of physicians. Fifty-four patients (68%) expressed the importance of maintaining sexual activity. Yet only 33 (41%) remained sexually active during CT. Decreased libido was reported by 49 (61%) patients. Fifty-eight (73%) patients perceived a negative impact of CT on their SH. Forty-seven patients (59%) expressed dissatisfaction with communication about SH with their partners. The median sexual satisfaction score was 36 [3-60], with no correlation observed with socioeconomic status (p=0.89), educational level (p=0.09) or site of cancer (p=0.12). It was significantly higher among unmarried patients (OR=5.42, p=0.027) and in those with metastatic disease (OR=3.26, p=0.012).
Conclusions
The diagnosis and treatment of cancer significantly affect SH. Thus, providing sexual counseling to patients, especially in Arab countries where cancer and sexuality remain taboo, is essential to effectively meet their needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11